'Certainly not' the same market penetration flawed , but 'usage' during the oxy trials could instigate several conference presentations/publications .
If say Esra elected to publish what contribution to future commercial success might you see gained ?
partnering for success, page-28
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $7.923M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 54 | 86239613 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.3¢ | 63389028 | 18 |
View Market Depth
| Last trade - 16.12pm 31/07/2024 (20 minute delay) ? |
| AVE (ASX) Chart |
Day chart unavailable